Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorder

被引：0
|
作者：
Stein, D. [1 ,2 ]
Ahokas, A. [3 ]
Jarema, M. [4 ]
Avedisova, A. S. [5 ]
Vavrusova, L. [6 ]
Chaban, O. [7 ]
Olivier, V. [8 ]
Gruget, C. [8 ]
Picarel-Blanchot, F. [8 ]
De Bodinat, C. [8 ]
机构：
[1] Univ Cape Town, Cape Town, South Africa
[2] Mt Sinai Sch Med, Dept Psychiat, Cape Town, South Africa
[3] Mehilainen Clin, Dept Psychiat, Helsinki, Finland
[4] Ctr Terapii Dialog, Warsaw, Poland
[5] Psychiat Hosp 12, Moscow, Russia
[6] Univ Hosp Bratislava, Dept Psychiat, Bratislava, Slovakia
[7] Railway Clin Hosp, Psychoneurol Dept, Kiev, Ukraine
[8] Inst Rech Int Servier, Pole Innovat Therapeut Neuropsychiat, Suresnes, France
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31678-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.4.b.003
引用
收藏
页码：S601 / S602
页数：2
相关论文
共 50 条
  • [11] EFFICACY AND SAFETY OF 3 AGOMELATINE DOSE REGIMENS (10, 25, 25-50 MG) VERSUS PLACEBO IN OUT-PATIENTS SUFFERING FROM MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER
    Kennedy, S. H.
    Avedisova, A.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [12] Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients
    Iwata, Nakao
    Tourian, Karen A.
    Hwang, Eunhee
    Mele, Linda
    Vialet, Cecile
    JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (01) : 5 - 14
  • [13] SUSTAINED EFFICACY AND SAFETY OF AGOMELATINE 10, 25 AND 25-50MG VERSUS PLACEBO OVER 24 WEEKS IN OUT-PATIENTS SUFFERING FROM MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER
    Kennedy, S. H.
    Avedisova, A.
    Picarel, F.
    De Bodinat, C.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [14] Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies
    Dan J. Stein
    Jon-Paul Khoo
    Françoise Picarel-Blanchot
    Valérie Olivier
    Michael Van Ameringen
    Advances in Therapy, 2021, 38 : 1567 - 1583
  • [15] Efficacy of agomelatine 25-50 mg in major depressive disorder
    Kennedy, S. H.
    Olie, J. P.
    Loo, H.
    Emsley, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S231 - S231
  • [16] Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study
    Bhumika Chowdhary
    Vikram K. Mahajan
    Karaninder S. Mehta
    Pushpinder S. Chauhan
    Vikas Sharma
    Anuj Sharma
    Sanket Vashist
    Prabal Kumar
    Archives of Dermatological Research, 2021, 313 : 109 - 117
  • [17] Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study
    Chowdhary, Bhumika
    Mahajan, Vikram K.
    Mehta, Karaninder S.
    Chauhan, Pushpinder S.
    Sharma, Vikas
    Sharma, Anuj
    Vashist, Sanket
    Kumar, Prabal
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2021, 313 (02) : 109 - 117
  • [18] Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies
    Stein, Dan J.
    Khoo, Jon-Paul
    Picarel-Blanchot, Francoise
    Olivier, Valerie
    Van Ameringen, Michael
    ADVANCES IN THERAPY, 2021, 38 (03) : 1567 - 1583
  • [19] Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
    Kennedy, Sidney H.
    Avedisova, Alla
    Belaidi, Carole
    Picarel-Blanchot, Francoise
    de Bodinat, Christian
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (02) : 378 - 389
  • [20] CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY OF 4 DOSES OF SURICLONE, DIAZEPAM, AND PLACEBO IN GENERALIZED ANXIETY DISORDER
    ANSSEAU, M
    OLIE, JP
    VONFRENCKELL, R
    JOURDAIN, G
    STEHLE, B
    GUILLET, P
    PSYCHOPHARMACOLOGY, 1991, 104 (04) : 439 - 443
12345